Impact of Acutely Increased Endogenous- and Exogenous Ketone Bodies on FGF21 Levels in Humans

References

• McGarry JD, Foster DW. Regulation of hepatic fatty acid oxidation and ketone body production. Annu Rev Biochem. 1980;49:395–420.
   PubMed Web of Science ®Google Scholar
• Laffel L. Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes. Diabetes Metab Res Rev. 1999;15:412–426.
   PubMed Web of Science ®Google Scholar
• Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009;32:1335–1343.
   PubMed Web of Science ®Google Scholar
• Umpierrez G, Korytkowski M. Diabetic emergencies - ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. Nat Rev Endocrinol. 2016;12:222–232.
   PubMed Web of Science ®Google Scholar
• Nishimura T, Nakatake Y, Konishi M, Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta. 2000;1492:203–206.
   PubMed Web of Science ®Google Scholar
• Inagaki T, Dutchak P, Zhao G, et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 2007;5(6):415–425.
   PubMed Web of Science ®Google Scholar
• Staiger H, Keuper M, Berti L, Hrabe de Angelis M, Haring HU. Fibroblast growth factor 21-metabolic role in mice and men. Endocr Rev. 2017;38:468–488.
   PubMed Web of Science ®Google Scholar
• Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 2007;5:426–437.
   PubMed Web of Science ®Google Scholar
• Lundasen T, Hunt MC, Nilsson LM, et al. PPARalpha is a key regulator of hepatic FGF21. Biochem Biophys Res Commun. 2007;360(2):437–440.
   PubMed Web of Science ®Google Scholar
• Badman MK, Koester A, Flier JS, Kharitonenkov A, Maratos-Flier E. Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology. 2009;150:4931–4940.
   PubMed Web of Science ®Google Scholar
• Fazeli PK, Lun M, Kim SM, et al. FGF21 and the late adaptive response to starvation in humans. J Clin Invest. 2015;125(12):4601–4611.
   PubMed Web of Science ®Google Scholar
• Galman C, Lundasen T, Kharitonenkov A, et al. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab. 2008;8(2):169–174.
   PubMed Web of Science ®Google Scholar
• Christodoulides C, Dyson P, Sprecher D, Tsintzas K, Karpe F. Circulating fibroblast growth factor 21 is induced by peroxisome proliferator-activated receptor agonists but not ketosis in man. J Clin Endocrinol Metab. 2009;94:3594–3601.
   PubMed Web of Science ®Google Scholar
• Dushay J, Chui PC, Gopalakrishnan GS, et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology. 2010;139(2):456–463.
   PubMed Web of Science ®Google Scholar
• Gaich G, Chien JY, Fu H, et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 2013;18(3):333–340.
   PubMed Web of Science ®Google Scholar
• Li L, Yang G, Ning H, Yang M, Liu H, Chen W. Plasma FGF-21 levels in type 2 diabetic patients with ketosis. Diabetes Res Clin Pract. 2008;82:209–213.
   PubMed Web of Science ®Google Scholar
• Vilà-Brau A, De Sousa-Coelho AL, Mayordomo C, Haro D, Marrero PF. Human HMGCS2 regulates mitochondrial fatty acid oxidation and FGF21 expression in HepG2 cell line. J Biol Chem. 2011;286:20423–20430.
   PubMed Web of Science ®Google Scholar
• Shimazu T, Hirschey MD, Newman J, et al. Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science. 2013;339(6116):211–214.
   PubMed Web of Science ®Google Scholar
• Leng Y, Wang J, Wang Z, et al. Valproic acid and other HDAC inhibitors upregulate FGF21 gene expression and promote process elongation in glia by inhibiting HDAC2 and 3. Int J Neuropsychopharmacol. 2016;19(8):1–13.
   PubMed Web of Science ®Google Scholar
• Newman JC, Verdin E. β-hydroxybutyrate: much more than a metabolite. Diabetes Res Clin Pract. 2014;106:173–181.
   PubMed Web of Science ®Google Scholar
• Svart M, Kampmann U, Voss T, et al. Combined insulin deficiency and endotoxin exposure stimulate lipid mobilization and alter adipose tissue signaling in an experimental model of ketoacidosis in subjects with type 1 diabetes: a randomized controlled crossover trial. Diabetes. 2016;65(5):1380–1386.
   PubMed Web of Science ®Google Scholar
• Voss TS, Vendelbo MH, Kampmann U, et al. Substrate metabolism, hormone and cytokine levels and adipose tissue signalling in individuals with type 1 diabetes after insulin withdrawal and subsequent insulin therapy to model the initiating steps of ketoacidosis. Diabetologia. 2019;62(3):494–503.
   PubMed Web of Science ®Google Scholar
• Svart M, Gormsen LC, Hansen J, et al. Regional cerebral effects of ketone body infusion with 3-hydroxybutyrate in humans: reduced glucose uptake, unchanged oxygen consumption and increased blood flow by positron emission tomography. A randomized, controlled trial. PLoS One. 2018;13(2):e0190556.
   PubMed Web of Science ®Google Scholar
• Svart MV, Rittig N, Kampmann U, Voss TS, Moller N, Jessen N. Metabolic effects of insulin in a human model of ketoacidosis combining exposure to lipopolysaccharide and insulin deficiency: a randomised, controlled, crossover study in individuals with type 1 diabetes. Diabetologia. 2017;60:1197–1206.
   PubMed Web of Science ®Google Scholar
• Lauritzen ES, Rittig N, Bach E, Moller N, Bjerre M. LPS infusion suppresses serum FGF21 levels in healthy adult volunteers. Endocr Connect. 2017;6:39–43.
   PubMed Web of Science ®Google Scholar
• Sorensen LK, Rittig NF, Holmquist EF, et al. Simultaneous determination of beta-hydroxybutyrate and beta-hydroxy-beta-methylbutyrate in human whole blood using hydrophilic interaction liquid chromatography electrospray tandem mass spectrometry. Clin Biochem. 2013;46(18):1877–1883.
   PubMed Web of Science ®Google Scholar
• Cahill GF Jr. Fuel metabolism in starvation. Annu Rev Nutr. 2006;26:1–22.
   PubMed Web of Science ®Google Scholar
• Arafat AM, Kaczmarek P, Skrzypski M, et al. Glucagon increases circulating fibroblast growth factor 21 independently of endogenous insulin levels: a novel mechanism of glucagon-stimulated lipolysis? Diabetologia. 2013;56(3):588–597.
   PubMed Web of Science ®Google Scholar
• Hansen JS, Clemmesen JO, Secher NH, et al. Glucagon-to-insulin ratio is pivotal for splanchnic regulation of FGF-21 in humans. Mol Metab. 2015;4(8):551–560.
   PubMed Web of Science ®Google Scholar
• Alonge KM, Meares GP, Hillgartner FB. Glucagon and insulin cooperatively stimulate fibroblast growth factor 21 gene transcription by increasing the expression of activating transcription factor 4. J Biol Chem. 2017;292:5239–5252.
   PubMed Web of Science ®Google Scholar
• Orskov L, Alberti KG, Mengel A, et al. Decreased hepatic glucagon responses in type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1991;34(7):521–526.
   PubMed Web of Science ®Google Scholar
• Mai K, Bobbert T, Groth C, et al. Physiological modulation of circulating FGF21: relevance of free fatty acids and insulin. Am J Physiol Endocrinol Metab. 2010;299(1):E126–130.
   PubMed Web of Science ®Google Scholar
• Stubbs BJ, Cox PJ, Evans RD, et al. On the metabolism of exogenous ketones in humans. Front Physiol. 2017;8:848.
   PubMed Web of Science ®Google Scholar
• Møller N, Jørgensen JO, Møller J, et al. Substrate metabolism during modest hyperinsulinemia in response to isolated hyperketonemia in insulin-dependent diabetic subjects. Metabolism. 1990;39(12):1309–1313.
   PubMed Web of Science ®Google Scholar